Originally posted by Jackpot
Here's 2 from top of my head - CDX and RHT ,both FDA approved and doing well.
Once you do the calculations they are in better position without debt, don't deal with Chinese BS and revenue wise doing ok , but mcap half of JAT.
But extremely better future then JAT imo
DYOR .
The comparison between JAT and RHT is somewhat bewildering to me as each stock is in a different space, is a different proposition and has a different (prospective) customer base.
But seeing as it's been brought up here I will say that a radiographer friend of mine has assured me RHT will not gain traction in Australia, mainly because it doesn't offer anything that can't already be provided by a simple blood test.
I certainly wish I'd jumped on for the ride from 3.5 cents to >10 cents but that's a separate matter to the longer term prospects of RHT.
